

## Product Update:

### alendronic acid 70mg effervescent tablet (Binosto<sup>®</sup>) SMC No.(1137/16) Internis Pharmaceuticals Ltd

---

04 March 2016

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**alendronic acid effervescent tablets (Binosto<sup>®</sup>)** is accepted for restricted use within NHS Scotland.

**Indication under review:** Treatment of postmenopausal osteoporosis.

**SMC restriction:** for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.

Alendronic acid 70mg effervescent tablets have demonstrated bioequivalence to alendronic acid 70mg tablets. The effervescent tablet formulation provides an alternative for patients who cannot swallow tablets. It is more expensive than generic alendronic acid tablets but is similar to the cost of existing oral solutions.

#### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 16 November 2015.*

**Chairman,  
Scottish Medicines Consortium**